Tammela T, Kontturi M, Puranen J
Department of Surgery, University Central Hospital, Oulu, Finland.
Ann Chir Gynaecol. 1987;76(3):170-2.
The efficacy of phenoxybenzamine in preventing postoperative urinary retention after total hip arthroplasty was investigated in a double-blind placebo-controlled study on 60 consecutive male patients with obstructive urinary symptoms. The patients were randomized into two groups, one being given 10 mg phenoxybenzamine orally and the other a placebo immediately after the termination of the operation and 8 and 16 hours later. Only 10% of the patients in the phenoxybenzamine group were affected by retention compared with 48% in the placebo group (p less than 0.01). It is concluded that phenoxybenzamine effectively prevents urinary retention after total hip arthroplasty in male patients with obstructive urinary symptoms. The drug is recommended for routine prophylactic use with patients not presenting with impaired cerebral circulation or serious coronary heart disease, to prevent infection leading to bacteraemia or other complications of urinary catheterization.
在一项针对60例连续患有梗阻性泌尿系统症状的男性患者的双盲安慰剂对照研究中，研究了酚苄明预防全髋关节置换术后尿潴留的疗效。患者被随机分为两组，一组在手术结束后立即口服10毫克酚苄明，另一组口服安慰剂，术后8小时和16小时重复给药。酚苄明组只有10%的患者出现尿潴留，而安慰剂组为48%（p<0.01）。结论是，酚苄明能有效预防患有梗阻性泌尿系统症状的男性患者全髋关节置换术后的尿潴留。建议在没有脑循环障碍或严重冠心病的患者中常规预防性使用该药物，以预防导尿引起的感染导致菌血症或其他并发症。
